Incyte Corporation

Peter Niels Carlsen

Xiaozhao Wang

Wenqing Yao

Wenyu Zhu

Chao Qi

Haolin Yin

Liangxing Wu

Alexander Sokolsky

Taisheng Huang

Pei Gan

Yong Li

Gia Hoang

Bin Hu

Gencheng Li

Rocco Policarpo

Chunhong He

Fenglei Zhang

Juan C Almagro

Qinda Ye

Artem Shvartsbart

Padmaja Polam

Le Zhao

Ken Mukai

Yingnan Chen

Jeremy Roach

Rebecca A Buonpane

Horacio G Nastri

Shaun M Stewart

Jing Zhou

Robert Susick

Hui Wang

Matthew Mccammant

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Naphthyridine compounds as inhibitors of KRAS

Quinoline compounds as inhibitors of KRAS

Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

Hetero-tricyclic compounds as inhibitors of KRAS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Fused pyrazine derivatives as A2A / A2B inhibitors

Vinyl imidazole compounds as inhibitors of KRAS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Pyrrole tricyclic compounds as A2A / A2B inhibitors

Growing community of inventors

Claymont, DE, United States of America

Peter Niels Carlsen